Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real‐world study in Taiwan

• Published in: ESC Heart Failure Vol. 7; no. 5; pp. 3003 - 3012
• Main Authors: Chang, Po‐Cheng, Wang, Chun‐Li, Hsiao, Fu‐Chih, Wen, Ming‐Shien, Huang, Chien‐Ying, Chou, Chung‐Chuan, Chu, Pao‐Hsien
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.10.2020; John Wiley and Sons Inc; Wiley
• Subjects: Age; Angiotensin receptor blockers; Cardiovascular disease; Ejection fraction; Heart attacks; Heart failure; Hospitalization; Hospitals; Laboratories; Medical records; Original; Original s; Patients; Sacubitril/valsartan (LCZ696); Stroke; Taiwan; Heart failure; Sacubitril/valsartan (LCZ696); Angiotensin receptor blockers
• ISSN: 2055-5822; 2055-5822
• DOI: 10.1002/ehf2.12924

Aims This study aimed to compare the efficacy of angiotensin receptor–neprilysin inhibitor (ARNI) therapy with angiotensin receptor blocker (ARB) therapy for cardiovascular outcomes in patients with heart failure (HF) with reduced ejection fraction. Methods and results Data were obtained from the Chang Gung Research Database. The cohort entry date of the ARB group was assigned as that of the ARNI group to avoid immortal time bias. Additionally, 1:1 propensity score matching based on age, sex, and baseline left ventricular ejection fraction was conducted. The expectation–maximization imputation method with inverse probability of treatment weighting was used to compare outcomes between the two groups. The primary outcome was a composite of cardiovascular death and hospitalization for worsening HF. Patients who received ARNI therapy had a significantly lower risk of the primary composite outcome occurring than patients who received ARBs (hazard ratio, 0.74; 95% confidence interval, 0.57–0.96). The reduction of hospitalization for worsening HF contributed most to the primary outcome benefits. In addition to the primary outcome, the ARNI group had a significantly lower risk of non‐fatal myocardial infarction. The improvement of ejection fraction was not significantly different between the groups. The medication doses of ARNI were lower than in clinical trials. Conclusions In patients with HF with reduced ejection fraction, sacubitril/valsartan was superior to ARB therapy in reducing the occurrence of the primary outcome endpoint of hospitalization for worsening HF and cardiovascular death.